The demand for Anti-Diabetes Drugs in Asia has been growing steadily in recent years, driven by various factors such as an aging population and changing lifestyles.
Customer preferences: There is a growing demand for oral medications that are convenient to take and have fewer side effects. Patients are also looking for drugs that can help them manage their blood sugar levels effectively and reduce the risk of complications associated with diabetes.
Trends in the market: In China, the Anti-Diabetes Drugs market is dominated by local manufacturers who offer low-priced alternatives to international brands. The market is also witnessing a shift towards newer classes of drugs such as GLP-1 receptor agonists and SGLT2 inhibitors, which have shown promising results in clinical trials.In India, the market is highly fragmented with a large number of small and medium-sized players. The market is dominated by metformin, a first-line therapy for diabetes, which accounts for a significant share of the market. However, there is a growing demand for newer classes of drugs such as DPP-4 inhibitors and GLP-1 receptor agonists.In Japan, the market is dominated by multinational pharmaceutical companies who offer a range of drugs for diabetes management. The market is witnessing a shift towards newer classes of drugs such as SGLT2 inhibitors and DPP-4 inhibitors, which have shown significant benefits in clinical trials.
Local special circumstances: In Southeast Asia, the prevalence of diabetes is high due to changing lifestyles and a growing middle class. However, access to healthcare is limited in many countries, which has led to a significant unmet need for diabetes management.In South Korea, the government has implemented various policies to promote the use of generic drugs, which has led to a significant increase in the use of generic anti-diabetes drugs.
Underlying macroeconomic factors: The Anti-Diabetes Drugs market in Asia is driven by various macroeconomic factors such as an aging population, increasing urbanization, and rising disposable incomes. The prevalence of diabetes is also increasing due to changing lifestyles and dietary habits. Governments in many countries are also investing in healthcare infrastructure to improve access to diabetes management and reduce the burden of diabetes-related complications on the healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
